# SYNVIVO, INC.: Development of the First Standardized, Commercial Retinal Barrier-on-Chip Using Donor-Matched Human Primary Retinal Pigment Epithelial and Choroidal Endothelial Cells for AMD Therapeutic Testing

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | SYNVIVO, INC. |
| Location | HUNTSVILLE, AL |
| Project | Development of the First Standardized, Commercial Retinal Barrier-on-Chip Using Donor-Matched Human Primary Retinal Pigment Epithelial and Choroidal Endothelial Cells for AMD Therapeutic Testing |
| Project number | 1R41EY038621-01 |
| Mechanism | R41 |
| Institute | National Eye Institute |
| Award | $290,400 |
| Awarded | 2026-09-03 |
| Project period | 2026-09-15 to 2027-08-31 |
| UEI | EHKCVZNSB5E5 |

## Why this score
- Award of $290,400.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11314934). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.